Table 1.
Comparison of clinical parameters between the NK/T‐cell lymphoma subtypes
| Korean Cancer Study Group | International Peripheral T‐cell Lymphoma Project | |||||
|---|---|---|---|---|---|---|
| UAT | Non‐UAT | P | Nasal | Extranasal | P | |
| Patients, number (%) | 221 (79) | 59 (21) | 92 (72) | 35 (28) | ||
| Male, % | 67 | 59 | 0.244 | 64 | 66 | 1.000 |
| Median age, years | 47 | 42 | 0.199 | 52 | 45 | 0.670 |
| Ann Arbor stage III/IV, % | 15 | 59 | <0.001 | 27 | 68 | <0.001 |
| Number of extranodal sites ≥ 2 | 17 | 44 | <0.001 | 16 | 55 | <0.001 |
| Elevated LDH, % | 38 | 66 | <0.001 | 45 | 60 | 0.009 |
| Hemophagocytosis, % | 7 | 12 | 0.188 | 3 | 3 | 1.000 |
| B symptoms, % | 38 | 58 | 0.007 | 39 | 54 | 0.161 |
| ECOG performance status ≥2, % | 18 | 42 | <0.001 | 9 | 37 | <0.001 |
| Bone marrow involvement, % | 3 | 22 | <0.001 | 10 | 14 | 0.530 |
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; UAT, upper aerodigestive tract.